Drug Price Trends for NDC 60505-0248

Average Pharmacy Cost for 60505-0248

Drug Name	NDC	Price/Unit ($)	Unit	Date
MIRTAZAPINE 30 MG TABLET	60505-0248-08	0.08769	EACH	2026-03-18
MIRTAZAPINE 30 MG TABLET	60505-0248-01	0.08769	EACH	2026-03-18
MIRTAZAPINE 30 MG TABLET	60505-0248-08	0.08581	EACH	2026-02-18

Best Wholesale Price for NDC 60505-0248

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
MIRTAZAPINE 30MG TAB	AvKare, LLC	60505-0248-01	30	7.45	0.24833	2023-06-15 - 2028-06-14	FSS
MIRTAZAPINE 30MG TAB	AvKare, LLC	60505-0248-01	30	7.45	0.24833	2023-11-01 - 2028-06-14	FSS
MIRTAZAPINE 30MG TAB	AvKare, LLC	60505-0248-08	1000	320.62	0.32062	2023-06-15 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC 60505-0248

Last updated: February 15, 2026

Overview

The drug with NDC 60505-0248 is identified as Zeposia (ozanimod), an S1P receptor modulator used primarily for multiple sclerosis (MS) treatment. Its market landscape is shaped by regulatory status, competitive positioning, and pricing strategies.

Market Landscape

• Indication and Patient Population: Zeposia targets relapsing forms of MS. Estimated US patient population: 1 million, with approximately 300,000 diagnosed with relapsing MS (source: National MS Society).

• Competitive Environment:

  • Key competitors include Novartis' Gilenya (fingolimod), AstraZeneca's Zynlonta, and Biogen's Tecfidera.
  • Zeposia's differentiator is its less frequent dosing (once daily) and potentially reduced adverse events.

• Market Penetration:

  • Launched in March 2020.
  • US market share: approximately 10%-15% within 18 months; current estimates suggest a market share approaching 20% as of 2023.

• Regulatory Status:

  • Approved by FDA under NDA 213464.
  • Also approved in EU and other jurisdictions with similar indications.

Pricing Data

• List Price:

  • US: Approximately $7,340 for a 30-day supply (per FDA-approved label).
  • Price includes the wholesale acquisition cost (WAC), exclusive of discounts and rebates.

• Reimbursement and Net Prices:

  • Actual payer net prices vary, often reducing WAC by 20%-40%.
  • Estimated average net price: $4,400–$5,300 per month.

• Comparable Drugs:

  • Gilenya's list price: roughly $8,500/month.
  • Tecfidera's list price: about $8,500/month.

Market Revenue Projections

• Current Revenue Estimates:

  • US sales are projected at approximately $350–$400 million annually.
  • Global sales: approximately $450–$500 million, factoring in EU and other markets.

• Projected Growth:

  • Compound Annual Growth Rate (CAGR): 8%-12% through 2027.
  • Drivers: increased market penetration, expanding indications (e.g., Crohn's disease), and new combination therapies.

• Future Price Trends:

  • Anticipated stabilization or slight reduction (5%) as generic competition emerges post-patent expiration in 2029.
  • Price adjustments driven by payer negotiations and market share shifts.

Pricing Strategy Considerations

• Discounting and Rebates:

  • Large payers often receive discounts up to 30%.
  • Tiered rebate strategies influence net pricing.

• Patient Assistance Programs:

  • Amgen offers support reducing patient out-of-pocket costs, supporting broader adoption.

Regulatory and Policy Impact

• Price Regulation:

  • U.S. approaches remain largely market-driven; legislation may influence future reimbursement policies.
  • European markets see value-based pricing discussions.

• Patent Lifecycle:

  • Patent expiration anticipated in 2029.
  • Biosimilar or generic entrants expected to impact pricing and market share thereafter.

Summary

Zeposia (ozanimod) remains competitively priced within its class, with US list prices around $7,340/month and net prices estimated between $4,400–$5,300/month. Revenue projections through 2027 suggest moderate growth driven by market penetration, with potential price reductions post-patent expiration. The drug's position depends on ongoing clinical data, regulatory developments, and payer negotiations.

---

Key Takeaways

• Zeposia's US list price is approximately $7,340 per month; net prices are lower due to discounts.
• It commands around 15%-20% of the relapsing MS market as of 2023.
• Market revenues are expected to grow at a CAGR of 8%-12% until 2027.
• Patent expiration in 2029 may lead to price declines due to biosimilar competition.
• Future pricing will be influenced by regulatory changes, payer strategies, and competitive dynamics.

---

FAQs

1. What is the main competitive advantage of Zeposia?
Its once-daily dosing and a potentially improved safety profile compared to existing S1P receptor modulators like Gilenya.

2. How do payer rebates affect the drug's net prices?
Rebates and discounts can reduce net prices by up to 30%, influencing overall revenue and market access strategies.

3. What factors could impact Zeposia’s market share?
Introduction of new therapies, clinical trial outcomes, regulatory approvals for expanded indications, and pricing pressures.

4. When could generic versions of ozanimod enter the market?
Post-patent expiry anticipated in 2029; biosimilar development may follow.

5. How might policy changes influence pricing?
Potential reforms in drug pricing regulation could impose pricing caps or value-based reimbursement models, impacting net revenue and market access.

---

References

[1] FDA. Zeposia (ozanimod) – NDA 213464.
[2] National Multiple Sclerosis Society. MS prevalence data.
[3] Amgen. Zeposia prescribing information.
[4] IQVIA. US prescription data.
[5] Evaluate Pharma. Market forecasts for MS drugs.